Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Current strategies for designing antidotes against botulinum neurotoxins.

Patel K, Cai S, Singh BR.

Expert Opin Drug Discov. 2014 Mar;9(3):319-33. doi: 10.1517/17460441.2014.884066. Epub 2014 Feb 13. Review.

PMID:
24520991
2.

Strategies to design inhibitors of Clostridium botulinum neurotoxins.

Cai S, Singh BR.

Infect Disord Drug Targets. 2007 Mar;7(1):47-57. Review.

PMID:
17346211
3.

Challenges in searching for therapeutics against Botulinum Neurotoxins.

Pirazzini M, Rossetto O.

Expert Opin Drug Discov. 2017 May;12(5):497-510. doi: 10.1080/17460441.2017.1303476. Epub 2017 Mar 17. Review.

PMID:
28271909
4.

Botulinum neurotoxins and botulism: a novel therapeutic approach.

Thanongsaksrikul J, Chaicumpa W.

Toxins (Basel). 2011 May;3(5):469-88. doi: 10.3390/toxins3050469. Epub 2011 May 13. Review.

5.

Small molecule inhibitors as countermeasures for botulinum neurotoxin intoxication.

Li B, Peet NP, Butler MM, Burnett JC, Moir DT, Bowlin TL.

Molecules. 2010 Dec 30;16(1):202-20. doi: 10.3390/molecules16010202. Review.

6.

Investigations into small molecule non-peptidic inhibitors of the botulinum neurotoxins.

Capková K, Salzameda NT, Janda KD.

Toxicon. 2009 Oct;54(5):575-82. doi: 10.1016/j.toxicon.2009.03.016. Epub 2009 Mar 25. Review.

7.

Gaining ground: assays for therapeutics against botulinum neurotoxin.

Hakami RM, Ruthel G, Stahl AM, Bavari S.

Trends Microbiol. 2010 Apr;18(4):164-72. doi: 10.1016/j.tim.2010.02.001. Epub 2010 Mar 4. Review.

PMID:
20202845
8.

Cargo-delivery platforms for targeted delivery of inhibitor cargos against botulism.

Wilson BA, Ho M.

Curr Top Med Chem. 2014;14(18):2081-93. Review.

9.

Development and evaluation of candidate vaccine and antitoxin against botulinum neurotoxin serotype F.

Yu YZ, Zhang SM, Ma Y, Zhu HQ, Wang WB, Du Y, Zhou XW, Wang RL, Wang S, Yu WY, Huang PT, Sun ZW.

Clin Immunol. 2010 Nov;137(2):271-80. doi: 10.1016/j.clim.2010.07.005. Epub 2010 Aug 8.

PMID:
20696619
10.

Extraction and inhibition of enzymatic activity of botulinum neurotoxins /B1, /B2, /B3, /B4, and /B5 by a panel of monoclonal anti-BoNT/B antibodies.

Kalb SR, Santana WI, Geren IN, Garcia-Rodriguez C, Lou J, Smith TJ, Marks JD, Smith LA, Pirkle JL, Barr JR.

BMC Biochem. 2011 Nov 15;12:58. doi: 10.1186/1471-2091-12-58.

11.

A Novel Botulinum Neurotoxin, Previously Reported as Serotype H, Has a Hybrid-Like Structure With Regions of Similarity to the Structures of Serotypes A and F and Is Neutralized With Serotype A Antitoxin.

Maslanka SE, Lúquez C, Dykes JK, Tepp WH, Pier CL, Pellett S, Raphael BH, Kalb SR, Barr JR, Rao A, Johnson EA.

J Infect Dis. 2016 Feb 1;213(3):379-85. doi: 10.1093/infdis/jiv327. Epub 2015 Jun 10.

12.

New targets in the search for preventive and therapeutic agents for botulism.

Anniballi F, Lonati D, Fiore A, Auricchio B, De Medici D, Locatelli CA.

Expert Rev Anti Infect Ther. 2014 Sep;12(9):1075-86. doi: 10.1586/14787210.2014.945917. Epub 2014 Aug 4. Review.

PMID:
25089560
13.

[Botulism: the agent, mode of action of the botulinum neurotoxins, forms of acquisition, treatment and prevention].

Marvaud JC, Raffestin S, Popoff MR.

C R Biol. 2002 Aug;325(8):863-78; discussion 879-83. French.

PMID:
12391898
14.

Persistence of Botulinum neurotoxin inactivation of nerve function.

Shoemaker CB, Oyler GA.

Curr Top Microbiol Immunol. 2013;364:179-96. doi: 10.1007/978-3-642-33570-9_9.

15.

Development and preclinical evaluation of a new F(ab')₂ antitoxin against botulinum neurotoxin serotype A.

Yu YZ, Zhang SM, Wang WB, Du Y, Zhu HQ, Wang RL, Zhou XW, Lin JB, Wang S, Yu WY, Huang PT, Sun ZW.

Biochimie. 2010 Oct;92(10):1315-20. doi: 10.1016/j.biochi.2010.06.010. Epub 2010 Jun 18.

PMID:
20600570
16.

A Novel Inhibitor Prevents the Peripheral Neuroparalysis of Botulinum Neurotoxins.

Azarnia Tehran D, Zanetti G, Leka O, Lista F, Fillo S, Binz T, Shone CC, Rossetto O, Montecucco C, Paradisi C, Mattarei A, Pirazzini M.

Sci Rep. 2015 Dec 16;5:17513. doi: 10.1038/srep17513.

17.

Botulism: cause, effects, diagnosis, clinical and laboratory identification, and treatment modalities.

Dembek ZF, Smith LA, Rusnak JM.

Disaster Med Public Health Prep. 2007 Nov;1(2):122-34. doi: 10.1097/DMP.0b013e318158c5fd. Review.

PMID:
18388640
18.

The use of small molecules to investigate molecular mechanisms and therapeutic targets for treatment of botulinum neurotoxin A intoxication.

Dickerson TJ, Janda KD.

ACS Chem Biol. 2006 Jul 21;1(6):359-69. Review. Erratum in: ACS Chem Biol. 2006 Aug 22;1(7):470.

PMID:
17163773
19.

An alternative in vivo method to refine the mouse bioassay for botulinum toxin detection.

Wilder-Kofie TD, Lúquez C, Adler M, Dykes JK, Coleman JD, Maslanka SE.

Comp Med. 2011 Jun;61(3):235-42.

20.

Development of vaccines for prevention of botulism.

Byrne MP, Smith LA.

Biochimie. 2000 Sep-Oct;82(9-10):955-66. Review.

PMID:
11086225

Supplemental Content

Support Center